All Board proposals approved by the Shareholders Allschwil, Switzerland – May 4, 2023At today’s Annual General Meeting of Idorsia Ltd held in Basel, Switzerland, shareholders voted in. | May 4, 2023
Idorsia will publish its first quarter financial results 2023 on Tuesday April 25, 2023, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day. . | April 18, 2023
Idorsia will publish its full year financial results 2022 on Tuesday February 7, 2023, at 07:00 CET An investor conference call and webcast will be held to discuss the results on the same day. . | January 31, 2023
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 9, 2023 Idorsia Ltd today announced that Jean-Paul Clozel, Chief Executive Officer of Idorsia, will present at the. | January 9, 2023
Results published in the Journal of Neurosurgery show that clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected. | April 4, 2022